M. Valverde

Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients

M. J. García, A. Domínguez-Gil, S. Cabrera, 2009, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients

M. J. García, A. Domínguez-Gil, S. Cabrera, 2011, Antimicrobial Agents and Chemotherapy.

POPULATION PHARMACOKINETICS OF EFAVIRENZ IN HIV PATIENTS : 1 INFLUENCE OF THE CYP 2 B 6 GENOTYPE 2 3 Running title : INFLUENCE OF CYP 2 B 6 GENOTYPE ON PHARMACOKINETICS 4 OF EFAVIRENZ 5 6

M. J. García, A. Domínguez-Gil, S. Cabrera, 2009 .

Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients.

M. J. García, A. Domínguez-Gil, A. Iglesias, 2008, AIDS.

1 POPULATION PHARMACOKINETIC / PHARMACOGENETIC MODEL IN 1 CAUCASIAN HIV-INFECTED PATIENTS FOR OPTIMIZATION OF 2 EFAVIRENZ THERAPY 3 4 Running title : POPULATION PHARMACOKINETIC / PHARMACOGENETIC 5 MODEL EFAVIRENZ 6 7

M. J. García, A. Domínguez-Gil, S. Cabrera, 2011 .

Time‐dependent pharmacokinetics of cyclosporine (Neoral®) in de novo renal transplant patients

E. Suárez, J. Lukas, R. Calvo, 2005, Journal of clinical pharmacy and therapeutics.

Hyperhidrosis in association with efavirenz.

A. Domínguez-Gil, S. Cabrera, M. Valverde, 2009, AIDS patient care and STDs.